Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 369 papers, 15 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
369citing papers in PubMed, 15 pooled it
107.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
369 citing papers in PubMed, 15 syntheses or guidelines pooled it, 465 citations in OpenAlex.
- Chemotherapy backbone and outcomes of immune checkpoint inhibitor combinations across solid tumors: a pan-tumor network meta-analysis.The oncologist · 2026Pooled it
- Advancements in Immunotherapy for Lung Cancer: A Meta-Analysis of Clinical Trial Outcomes.The clinical respiratory journal · 2026Pooled it
- Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.The Indian journal of medical research · 2026Pooled it
- EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.Thoracic cancer · 2026Pooled it
- Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model.Health technology assessment (Winchester, England) · 2026Pooled it
- Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Pooled it
- Efficacy of first-line treatment in driver gene-negative non-small cell lung cancer with liver metastases: a Bayesian network meta-analysis.Frontiers in immunology · 2026Pooled it
- A Comprehensive Evaluation of the Effectiveness and Safety of Pembrolizumab for the Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Current cancer drug targets · 2026Pooled it
- Efficacy and safety of first-line chemoimmunotherapy versus chemotherapy alone for advanced pulmonary lymphoepithelioma-like carcinoma: a systematic review and real-world cohort study.Frontiers in immunology · 2026Pooled it
- Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.Journal for immunotherapy of cancer · 2025Pooled it
- Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review.Cancer immunology, immunotherapy : CII · 2025Pooled it
- PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.World journal of surgical oncology · 2025Pooled it
- Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs: A Systematic Review.JAMA network open · 2025Pooled it
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.Nature communications · 2026Trial
- Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis.Journal for immunotherapy of cancer · 2026Trial
- Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.Cancer science · 2026Trial
- Longitudinal Analysis of Peripheral Blood CD4+ T-Cell Profiles and Clinical Outcomes in Metastatic Non-Small-Cell Lung Cancer Patients Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy.International journal of molecular sciences · 2026Trial
309 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 17 institutions in 14 countries.
Silvia NovelloDepartment of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, Italy.ORCID 0000-0001-7653-9748
Dariusz M KowalskiDepartment of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID 0000-0002-9452-3229
Alexander LuftDepartment of Oncology No. 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, Saint Petersburg, Russia.
Mahmut GümüşFaculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.ORCID 0000-0003-3550-9993
David VicenteDepartment of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Julien MazièresThoracic Oncology, Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, France.ORCID 0000-0002-5921-7613
Jeronimo Rodríguez-CidOncology Center, Medica Sur Hospital, Mexico City, Mexico.ORCID 0000-0001-8518-9065
Ali TafreshiWollongong Private Hospital and Wollongong Oncology, Wollongong, NSW, Australia.
Ying ChengDepartment of Oncology, Jilin Cancer Hospital, Changchun, China.ORCID 0000-0001-9908-597X
Ki Hyeong LeeChungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju, South Korea.ORCID 0000-0002-7830-5950
Alexander GolfMedical Oncology, Universitätskinikum Tübingen, Tuebingen, Germany.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan.ORCID 0000-0002-3427-4558
Andrew G RobinsonCancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada.ORCID 0000-0003-1152-4275
Balazs HalmosMontefiore Medical Center/Albert Einstein College of Medicine, The Bronx, NY.ORCID 0000-0001-7548-8360
Erin JensenBiostatistics and Research Decision Sciences, Merck & Co, Inc, Rahway, NJ.
Paul SchwarzenbergerGlobal Clinical Development, Merck & Co, Inc, Rahway, NJ.
M Catherine PietanzaGlobal Clinical Development, Merck & Co, Inc, Rahway, NJ.
Luis Paz-AresDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, Spain.ORCID 0000-0002-1947-3364
Merck & Co., Inc., Rahway, NJ, USA (United States) · USAlbert Einstein College of Medicine · USChungbuk National University Hospital · KRDecision Sciences (United States) · USHôpital Larrey · FRHospital Médica Sur · MXHospital Universitario 12 De Octubre · ESHospital Universitario Virgen Macarena · ESIstanbul Medeniyet University · TRJilin Province Tumor Hospital · CNKingston General Hospital · CALeningrad Regional Cancer Center · RUSendai Kousei Hospital · JPThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversitätsklinikum Tübingen · DEUniversity of Turin · ITWollongong Hospital · AU
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, Monoclonal, Humanizedpembrolizumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.